NCT01338389View on ClinicalTrials.gov

Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 25, 2012

Primary Completion Date

June 29, 2017

Study Completion Date

June 29, 2017

Conditions
Uveal Melanoma
Interventions
DIETARY_SUPPLEMENT

CITICOLINE

"Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years"

DIETARY_SUPPLEMENT

PLACEBO

"Oral administration of placebo:~Form: Powder for solution duration: 5 years"

Trial Locations (2)

06000

CHU de NICE, Nice

Ophtalmology Departement, St Roch Hopital, Nice University Hospital, Nice

Sponsors

Collaborators (1)

DENSMORE pharmaceuticals
All Listed Sponsors
collaborator

DENSMORE pharmaceuticals

UNKNOWN

lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT01338389 - Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy | Biotech Hunter | Biotech Hunter